Perttu Mikael Koskenvesa

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Awad, S. A., Kankainen, M., Ojala, T., Koskenvesa, P., Eldfors, S., Ghimire, B., Kumar, A., Kytölä, S., Kamel, M. M., Heckman, C. A., Porkka, K. & Mustjoki, S., 11 feb 2020, I : Blood advances. 4, 3, s. 546-559 14 s.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Soderlund, S., Persson, I., Ilanderd, M., Guilhot, J., Hjorth-Hansen, H., Koskenvesa, P., Richter, J., Saussele, S., Mustjoki, S. & Olsson-Strömberg, U., mar 2020, I : Leukemia Research. 90, 7 s., 106310.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

RUNX1mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

Awad, S. A., Dufva, O., Ianevski, A., Ghimire, B., Koski, J., Maliniemi, P., Thomson, D., Schreiber, A., Heckman, C. A., Koskenvesa, P., Korhonen, M., Porkka, K., Branford, S., Aittokallio, T., Kankainen, M. & Mustjoki, S., 11 aug 2020, I : Leukemia. 13 s.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Pfirrmann, M., Clark, R. E., Prejzner, W., Lauseker, M., Baccarani, M., Saussele, S., Guilhot, F., Heibl, S., Hehlmann, R., Faber, E., Turkina, A., Ossenkoppele, G., Hoglund, M., Zaritskey, A., Griskevicius, L., Olsson-Stromberg, U., Everaus, H., Koskenvesa, P., Labar, B., Sacha, T. & 10 andra, Zackova, D., Cervantes, F., Colita, A., Zupan, I., Bogdanovic, A., Castagnetti, F., Guilhot, J., Hasford, J., Hochhaus, A. & Hoffmann, V. S., aug 2020, I : Leukemia. 34, 8, s. 2138–2149 12 s.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Kreutzman, A., Yadav, B., Brummendorf, T. H., Gjertsen, B. T., Lee, M. H., Janssen, J., Kasanen, T., Koskenvesa, P., Lotfi, K., Markevärn, B., Olsson-Stromberg, U., Stentoft, J., Stenke, L., Söderlund, S., Udby, L., Richter, J., Hjörth-Hansen, H. & Mustjoki, S., 2 sep 2019, I : OncoImmunology. 8, 9, 13 s., e1638210.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review